Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Enhancing Systematic Reviews: AI Literature Review Integration for Efficiency and Rigor
AI Literature Review Integration is transforming systematic literature reviews (SLRs), as outlined in this preprint. It provides methodological guidance for incorporating artificial intelligence (AI) into SLRs with a human-in-the-loop approa...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency
Court Clerical Error Threatens Infarmed Vaccine Data Transparency
Infarmed vaccine data transparency hangs in the balance due to a clerical error by the Lisbon Administrative Court's secretariat, which sent a January...
EMA Executive Director Recruitment: Leading the Future of Medicines Regulation
The EMA Executive Director Recruitment procedure has opened, a pivotal role overseeing operations like medicine authorizations, safety monitoring, and EU-wide public health responses. This vacancy, with reference COM/2026/20118, reports to the EMA Management Board, managing a 2025 budget of about...